AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) – Equities research analysts at Jefferies Financial Group issued their Q3 2018 EPS estimates for shares of AcelRx Pharmaceuticals in a research note issued to investors on Monday, October 15th. Jefferies Financial Group analyst R. Song forecasts that the specialty pharmaceutical company will earn ($0.21) per share for the quarter. Jefferies Financial Group currently has a “Buy” rating and a $8.00 target price on the stock. Jefferies Financial Group also issued estimates for AcelRx Pharmaceuticals’ Q4 2018 earnings at ($0.14) EPS, FY2018 earnings at ($0.78) EPS, FY2019 earnings at ($0.99) EPS, FY2020 earnings at ($0.95) EPS, FY2021 earnings at ($0.39) EPS and FY2022 earnings at $0.44 EPS.
Several other analysts also recently weighed in on ACRX. Zacks Investment Research downgraded AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 9th. Oppenheimer reiterated a “hold” rating on shares of AcelRx Pharmaceuticals in a research report on Friday, August 3rd. Cantor Fitzgerald set a $6.00 price objective on AcelRx Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, October 1st. Finally, LADENBURG THALM/SH SH began coverage on AcelRx Pharmaceuticals in a research report on Thursday, August 16th. They issued a “buy” rating and a $7.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $7.50.
AcelRx Pharmaceuticals (NASDAQ:ACRX) last issued its earnings results on Thursday, August 2nd. The specialty pharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.01). The business had revenue of $0.82 million during the quarter, compared to analyst estimates of $0.93 million.
In related news, CEO Vincent J. Angotti acquired 10,000 shares of the stock in a transaction on Tuesday, August 7th. The stock was purchased at an average price of $2.90 per share, for a total transaction of $29,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Lawrence G. Hamel sold 6,953 shares of the business’s stock in a transaction that occurred on Monday, September 24th. The shares were sold at an average price of $4.50, for a total value of $31,288.50. Following the completion of the sale, the insider now owns 24,371 shares of the company’s stock, valued at approximately $109,669.50. The disclosure for this sale can be found here. Insiders acquired 57,300 shares of company stock valued at $159,552 in the last quarter. Corporate insiders own 25.50% of the company’s stock.
A number of hedge funds have recently made changes to their positions in ACRX. GSA Capital Partners LLP bought a new stake in AcelRx Pharmaceuticals in the first quarter valued at approximately $113,000. Lincoln Capital Corp bought a new position in shares of AcelRx Pharmaceuticals during the second quarter valued at approximately $116,000. Granite Investment Partners LLC bought a new position in shares of AcelRx Pharmaceuticals during the second quarter valued at approximately $182,000. Northern Trust Corp raised its holdings in shares of AcelRx Pharmaceuticals by 60.8% during the first quarter. Northern Trust Corp now owns 91,481 shares of the specialty pharmaceutical company’s stock valued at $192,000 after acquiring an additional 34,584 shares in the last quarter. Finally, FMR LLC raised its holdings in shares of AcelRx Pharmaceuticals by 1,094.6% during the second quarter. FMR LLC now owns 298,644 shares of the specialty pharmaceutical company’s stock valued at $1,008,000 after acquiring an additional 273,644 shares in the last quarter. Hedge funds and other institutional investors own 8.57% of the company’s stock.
AcelRx Pharmaceuticals Company Profile
AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.
Featured Article: How accurate is the Rule of 72?
Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.